Literature DB >> 2588999

The association between the neuroleptic malignant syndrome and malignant hyperthermia.

P J Adnet1, R M Krivosic-Horber, M M Adamantidis, G Haudecoeur, C A Adnet-Bonte, F Saulnier, B A Dupuis.   

Abstract

The neuroleptic malignant syndrome (NMS) is an uncommon but dangerous complication of treatment with neuroleptic drugs. A primary defect in skeletal muscle has been suggested in view of similarities in the clinical presentations of NMS and anaesthetic-induced malignant hyperthermia (MH). The in vitro halothane-caffeine contracture tests are the most reliable method of identifying individuals susceptible to MH. The aim of this study was to define if a relationship exists between NMS and MH susceptibility. Hence, the in vitro halothane and caffeine contracture tests were performed on muscle tissue obtained from eight NMS, ten MH-susceptible and ten control patients. The results, which are expressed in accordance with the criteria of the European MH Group, defined the eight NMS subjects as MH non-susceptible. The response to halothane and caffeine exposure of skeletal muscle from NMS and control subjects was the same and significantly different from that of muscle from patients susceptible to MH. Furthermore, muscle from subjects in NMS and control group responded similarly to increasing concentrations of chlorpromazine. These results do not point towards an association between NMS and MH.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2588999     DOI: 10.1111/j.1399-6576.1989.tb02990.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  8 in total

1.  Detecting susceptibility to malignant hyperthermia.

Authors:  F R Ellis
Journal:  BMJ       Date:  1992-03-28

2.  Missed neuroleptic malignant syndrome.

Authors:  D S Renwick; A Chandraker; P Bannister
Journal:  BMJ       Date:  1992-03-28

Review 3.  Psychiatry.

Authors:  K Granville-Grossman
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

4.  Malignant neuroleptic syndrome following deep brain stimulation surgery: a case report.

Authors:  Marios S Themistocleous; Efstathios J Boviatsis; Lampis C Stavrinou; Pantelis Stathis; Damianos E Sakas
Journal:  J Med Case Rep       Date:  2011-06-29

5.  Anesthetic management of a pediatric patient with neuroleptic malignant syndrome.

Authors:  Tarun Bhalla; Douglas Maxey; Amod Sawardekar; Joseph D Tobias
Journal:  J Anesth       Date:  2011-11-19       Impact factor: 2.078

Review 6.  Malignant hyperthermia.

Authors:  R Ben Abraham; P Adnet; V Glauber; A Perel
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

Review 7.  Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia.

Authors:  M F Bristow; S R Hirsch
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

8.  Neuroleptic malignant syndrome: case report and discussion.

Authors:  Geethan J Chandran; John R Mikler; David L Keegan
Journal:  CMAJ       Date:  2003-09-02       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.